echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Zotiraciclib combined with temozolomide in the treatment of recurrent high-grade astrocytoma

    Clin Cancer Res: Zotiraciclib combined with temozolomide in the treatment of recurrent high-grade astrocytoma

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The treatment of brain tumors is challenging, mainly due to its biological characteristics, including high heterogeneity and complex drug resistance mechanisms
    .


    Only a small number of drugs that have passed clinical trials have become established therapies, emphasizing the importance of preclinical research to study promising drug candidates, thereby increasing the chances of successful drug development


    This study aims to explore the toxicity characteristics of Zotiraciclib combined with temozolomide for recurrent high-grade astrocytoma and to determine the best dosing regimen
    .

    The toxicity characteristics of Zotiraciclib combined with temozolomide for recurrent high-grade astrocytoma and the determination of the best dosing regimen

    This is a two-stage phase I trial that uses Bayesian optimal interval design to determine the maximum tolerated dose (MTD) of Zotiraciclib and dose-intensive (Arm1) or rhythmic (Arm2) temozolomide; then expand at random The cohort compared the progression-free survival rate (PFS4) of the two groups at 4 months
    .

    The change of ANC (A) and the concentration of Zotiraciclib (B) during each patient's treatment

    The change of ANC (A) and the concentration of Zotiraciclib (B) during each patient's treatment

    A total of 53 patients were recruited with dose-limiting toxicities such as neutropenia, diarrhea, elevated liver enzymes, and fatigue
    .


    In both treatment arms, Zotiraciclib had an MTD of 250 mg and was therefore selected for the extended cohort


    Dose-limiting toxicities include neutropenia, diarrhea, elevated liver enzymes, and fatigue.


    Correlation between CYP1A2(rs2470890) polymorphism and the AUC inf value of Zotiraciclib

    Correlation between CYP1A2(rs2470890) polymorphism and the AUC inf value of Zotiraciclib inf

    In both treatment arms, the symptom burden worsened during the second course of treatment, and stabilized again during the fourth course of treatment
    .


    12-24 hours after oral administration of Zotiraciclib, the absolute neutrophil count and the production of neutrophil reactive oxygen species were significantly reduced, but both recovered after 72 hours


    12-24 hours after oral Zotiraciclib, absolute neutrophil counts and neutrophil ROS generation cells were significantly reduced, but recovered after 72 hours inf

    In summary, Zotiraciclib combined with temozolomide is safe for the treatment of recurrent high-grade astrocytoma
    .


    Neutropenia caused by Zotiraciclib can be severe, but most of it is short-lived and requires close monitoring rather than stopping treatment


    Zotiraciclib combined with temozolomide is safe for the treatment of recurrent high-grade astrocytoma


    Original source:

    Jing Wu, et al.


    Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.